BSE has announced the live activities schedule for the Offer to Buy (OTB) – Acquisition Window (Buyback) for Jagsonpal Pharmaceuticals Ltd (Symbol: JAGSNPHARM, Scrip Code: 507789, ISIN: INE048B01035). The buyback window opens on Friday, 8th May 2026 and closes on Thursday, 14th May 2026. The offer is for up to 16,00,000 equity shares at a price of Rs. 250.00 per share.

Key Points

• Security: Jagsonpal Pharmaceuticals Ltd | Symbol: JAGSNPHARM | ISIN: INE048B01035 | Scrip Code: 507789
• Offer Size: Up to 16,00,000 Equity Shares
• Offer Price: Rs. 250.00 per share
• Face Value: Rs. 2.00
• Market Lot: 1
• Opening Date: Friday, 8th May 2026
• Closing Date: Thursday, 14th May 2026
• Session Timings: 9:15 a.m. to 3:30 p.m. for most activities; Take-up on the last day extended to 4:00 p.m.
• Bids can only be placed for investors holding shares in demat form
• Trading Members must ensure UCC of investors is registered with correct PAN and Category

Regulatory Changes

No new regulatory changes introduced. This notice operationalises the existing OTB framework as per Exchange Notices 20150930-1 (dated 30 September 2015) and 20170203-29 (dated 3 February 2017).

Compliance Requirements

• Trading Members must ensure the Unique Client Code (UCC) of each investor is registered and updated with the correct PAN Number and Category in the Exchange UCC database before placing bids.
• Members and Custodians should note that if no securities are accepted, no End of Issue files will be generated on the Extranet.
• Participants must use the designated iBBS and RTRMS platforms for bid submission and modifications.
• For leased line access settings, refer to Exchange Circular No. 20170503-12.

Important Dates

Impact Assessment

This circular is operationally relevant to Trading Members and Custodian Members participating in the Jagsonpal Pharmaceuticals buyback. The offer is open to multiple investor categories including FIIs, FIs, Mutual Funds, Insurance Companies, other QIBs, NIBs, companies, and individual investors. The impact is limited to participants in this specific buyback and does not affect broader market operations. Members should prepare their systems and ensure UCC compliance before 8th May 2026.

BSE has announced the opening of an Offer to Buy (Acquisition Window) for the buyback of equity shares of Jagsonpal Pharmaceuticals Limited. The company proposes to repurchase up to 16,00,000 (Sixteen Lakhs) fully paid-up equity shares of face value Rs.2 each at Rs.250 per share via a tender offer route through the stock exchange mechanism, for an aggregate consideration not exceeding Rs.40 crores. The buyback window is open from May 08, 2026 to May 14, 2026.

Key Points

• Company: Jagsonpal Pharmaceuticals Limited
• Offer Type: Buyback via tender offer through stock exchange mechanism
• Shares Offered for Buyback: Up to 16,00,000 (Sixteen Lakhs) fully paid-up equity shares
• Face Value: Rs.2 per share
• Buyback Price: Rs.250 per share (payable in cash)
• Aggregate Consideration: Not exceeding Rs.40 crores (excluding transaction costs)
• Record Date: Monday, May 04, 2026
• Buyback Offer Size: Represents 18.35% of aggregate fully paid-up equity share capital and free reserves as per audited financials for FY ended March 31, 2025
• Basis: Proportionate basis among eligible equity shareholders/beneficial owners as on the record date

Regulatory Changes

This offer is conducted pursuant to SEBI’s mechanism for acquisition of shares through stock exchanges under tender offers, as established by:

• SEBI circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015
• SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016

BSE’s revised guidelines have been issued via notices: 20170210-16 (Feb 10, 2017), 20190424-35 (Apr 24, 2019), 20200528-32 (May 28, 2020), 20201102-43 (Nov 02, 2020), and 20210825-62 (Aug 25, 2021).

Compliance Requirements

• Trading Members and Custodians must note the opening of the acquisition window and facilitate client participation in the buyback.
• Eligible shareholders (those holding equity shares as on the record date of May 04, 2026) may tender their shares during the buyback window.
• All market participants must adhere to SEBI circular no. CFD/DCR2/CIR/P/2016/131 and BSE notice no. 20170210-16 and 20190424-35 when processing this offer.
• A Letter of Offer is attached to the notice and must be reviewed by market participants.

Important Dates

Impact Assessment

This buyback offers eligible shareholders of Jagsonpal Pharmaceuticals Limited an opportunity to tender their shares at Rs.250 per share through the stock exchange mechanism. The offer represents 18.35% of the company’s aggregate equity capital and free reserves, indicating a significant capital return initiative. At Rs.250 per share versus a Rs.2 face value, the buyback is at a substantial premium, which may be attractive to existing shareholders. Trading members and custodians must be prepared to process tender instructions from clients during the May 08–14, 2026 window. The buyback is limited to proportionate allotment, so not all tendered shares may be accepted if oversubscribed.

ICCL (Indian Clearing Corporation Ltd.) has published the settlement calendar for the Offer to Buy – Acquisition Window (Buyback) for Jagsonpal Pharmaceuticals Limited. The buyback window runs from May 8 to May 14, 2026, under Settlement No. 2026049, with final settlement on May 21, 2026.

Key Points

• Buyback bidding window: May 8, 2026 to May 14, 2026
• Settlement number: 2026049
• Obligation download date: May 20, 2026
• Settlement date: May 21, 2026
• Demat shares must be delivered exclusively via the Early Pay-in of Shares mechanism (available through both CDSL and NSDL)
• Market Type “(Buyback)” and Settlement No. 2026049 must be used in the depository system
• Members/Custodians are NOT required to upload any EPN file for early pay-in
• CDSL & NSDL early pay-in securities will be earmarked/blocked in client accounts under the requisite market type and settlement number

Regulatory Changes

No new regulatory changes introduced. Members/Custodians are directed to refer to existing Notice No. 20200528-32 (dated May 28, 2020) regarding settlement as per Revised Guidelines of Mechanism for Acquisition of Shares through Stock Exchange.

Compliance Requirements

• Members and Custodians must ensure early pay-in of securities is reflected in BSE/ICCL systems before the prescribed timelines for accepting/confirming bids on the BSE OTB platform
• Early pay-in must be completed sufficiently in advance of the closure of the BSE OTB Bidding window (for members placing bids) and the Confirmation window (for Custodians confirming bids)
• Use Market Type “(Buyback)” and Settlement No. 2026049 when processing in the depository system
• Members should refer to the MBRSTD_OTB_CM_mmm_SettNo file for client-wise Stamp Duty charges

Important Dates

Impact Assessment

This notice is operationally significant for Members and Custodians participating in the Jagsonpal Pharmaceuticals Limited buyback. The early pay-in requirement via depository mechanisms (CDSL/NSDL) means participants must plan share delivery well ahead of bid window closure. The absence of an EPN file upload requirement simplifies the process. Broader market impact is limited to participants directly involved in this specific buyback offer. For queries, ICCL Help Desk can be reached at 022-69158590/45720490/45720690 or iccl.helpdesk@icclindia.com.